COCRYSTAL PHARMA INC.

Cocrystal Pharma plans to extend enrolment for its Phase IIa trial of CC-42344 due to low infection rates. The trial assesses the influenza A treatment's safety and efficacy, showing promise against resistant strains.

Cocrystal Pharma extends Phase 2a study enrollment for CC-42344 due to low influenza infection rates. The drug shows a favorable safety profile with no serious adverse events or discontinuations. CC-42344 targets pandemic and seasonal influenza A, demonstrating potential as a best-in-class antiviral treatment.

Cocrystal Pharma extends Phase 2a study enrollment for CC-42344 due to low influenza infection rates, maintaining optimism about its safety and potential against influenza A, despite challenges in data analysis from low infectivity.

Cocrystal Pharma reports Q3 2024 financials, highlighting progress in antiviral drug development, including Phase 2a influenza A study results expected by year-end and Phase 1 norovirus/coronavirus study results in late 2024 or early 2025. The company emphasizes its structure-based drug discovery platform and expects sufficient cash to fund operations for the next 12 months.